Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL

Journal of Bone and Mineral Research

Volumn 21, Issue 3, 2006, Pages 438-445

  Middleton Hardie, Catherine ^a   Zhu, Qing ^a   Cundy, Harry ^a   Lin, Jian Ming ^a   Callon, Karen ^a   Tong, Pak Cheung ^a   Xu, Jiake ^b   Grey, Andrew ^a   Cornish, Jill ^a   Naot, Dorit ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bone remodeling; Genotype phenotype; Glycosylation; Idiopathic hyperphosphatasia; Osteoprotegerin; RANKL binding

Indexed keywords

ASPARTIC ACID; GLUTATHIONE TRANSFERASE; MUTANT PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT PROTEIN;

ANIMAL TISSUE; ARTICLE; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERPHOSPHATASEMIA; IDIOPATHIC DISEASE; JUVENILE PAGET DISEASE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PAGET BONE DISEASE; PROTEIN BINDING; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ASPARTIC ACID; CARRIER PROTEINS; CELLS, CULTURED; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; OSTEITIS DEFORMANS; OSTEOPROTEGERIN; PROTEIN TRANSPORT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SEQUENCE DELETION;

EID: 33644537916     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.051104     Document Type: Article

References (36)

1. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
3. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342.
4. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
5. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
6. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
7. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615.
8. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S 2002 Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:175-184.
9. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love D, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J 2002 A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119-2127.
10. Caffey J 1973 Familial hyperphosphatasia with ateliosis and hypermetabolism of growing membranous bone: Review of the clinical, radiographic and chemical features. In: Kaufmann HJ (ed.) Progress in Pediatric Radiology, vol. 4. Karger, Basel, Switzerland, pp. 438-468.
11. Blanco O, Stivel M, Mautalen C, Schajowicz F 1977 Familial idiopathic hyperphosphatasia: A study of two young siblings treated with porcine calcitonin. J Bone Joint Surg Br 59:421-427.
12. Dunn V, Condon VR, Rallison ML 1979 Familial hyperphosphatasemia: Diagnosis in early infancy and response to human thyrocalcitonin therapy. AJR Am J Roentgenol 132:541-545.
13. Bakwin H, Eiger MS 1956 Fragile bones and macrocranium. J Pediatr 49:558-564.
14. Iancu TC, Almagor G, Friedman E, Hardoff R, Front D 1978 Chronic familial hyperphosphatasemia. Radiology 129:669-676.
15. Eyring EJ, Eisenberg E 1968 Congenital hyperphosphatasia. A clinical, pathological, and biochemical study of two cases. J Bone Joint Surg Am 50:1099-1117.
16. Bakwin H, Golden A, Fox S 1964 Familial osteoectasia with macrocranium. Am J Roentgenol Radium Ther Nucl Med 91:609-617.
17. Thompson RC Jr, Gaull GE, Horwitz SJ, Schenk RK 1969 Hereditary hyperphosphatasia. Studies of three siblings. Am J Med 47:209-219.
18. Choremis C, Yannakos D, Papadotos C, Baroustou E 1958 Osteitis deformans (Paget's disease) in an 11 year old boy. Helv Paediatr Acta 13:185-188.
19. Singer F, Siris E, Shane E, Dempster D, Lindsay R, Parisien M 1994 Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. J Bone Miner Res 9:733-738.
20. Woodhouse NJ, Fisher MT, Sigurdsson G, Joplin GF, MacIntyre I 1972 Paget's disease in a 5-year-old: Acute response to human calcitonin. BMJ 4:267-269.
21. Stemmermann GN 1966 An histologic and histochemical study of familial osteoectasia. (Chronic idiopathic hyperphosphatasia). Am J Pathol 48:641-651.
22. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM 2005 Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 353:918-923.
23. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR 2001 Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29:162-168.
24. Xu J, Tan JW, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH 2000 Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res 15:2178-2186.
25. Chong B, Hegde M, Fawkner M, Simonet WS, Cassinelli HR, Coker M, Kanis JA, Seidel J, Tau C, Tuysuz B, Yuksel B, Love D, Cundy T 2003 Idiopathic hyperphosphatasia and TNFRSF11B mutations: Relationships between phenotype and genotype. J Bone Miner Res 18:2095-2104.
26. Theoleyre S, Wittrant Y, Couillaud S, Vusio P, Berreur M, Dunstan C, Blanchard F, Redini F, Heymann D 2004 Cellular activity and signalling induced by osteoprotegerin in osteoclasts: Involvement of receptor activator of nuclear factor KB ligand and MAPK. Biochim Biophys Acta 1644:1-7.
27. Willard D, Chen WJ, Barrett G, Blackburn K, Bynum J, Consler T, Hoffman C, Horne E, Iannone MA, Kadwell S, Parham J, Ellis B 2000 Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain. Protein Expr Purif 20:48-57.
28. Bause E, Legler G 1981 The role of the hydroxy amino acid in the triplet sequence Asn-Xaa-Thr(Ser) for the N-glycosylation step during glycoprotein biosynthesis. Biochem J 195:639-644.
29. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W 1993 Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 73:431-445.
30. Ellgaard L, Helenius A 2003 Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4:181-191.
31. Plemper RK, Wolf DH 1999 Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem Sci 24:266-270.
32. Ellgaard L, Molinari M, Helenius A 1999 Setting the standards: Quality control in the secretory pathway. Science 286:1882-1888.
33. Welch WJ 2004 Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol 15:31-38.
34. Le A, Steiner JL, Frerrell GA, Shaker JC, Sifer RN 1994 Association between calnexin and a secretion-incompetant cariant of human alpha1-antitrypsin. J Biol Chem 269:7514-7519.
35. Perlmutter DH 2002 Liver injury in alpha1-antitrypsin deficiency: An aggregated protein induces mitochondrial injury. J Clin Invest 110:1579-1583.
36. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE 1990 Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827-834.